FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Files An 8-K Other EventsItem 8.01. Other Events.
Attached hereto as Exhibit 99.1 and incorporated herein by reference is a presentation including an updated corporate overview of Fortress Biotech, Inc. and certain of its biopharmaceutical subsidiaries.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.1 | Presentation of December 2017. |
Fortress Biotech, Inc. ExhibitEX-99.1 2 tv481322_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Non – Confidential Materials Corporate Presentation December 2017 Non – Confidential Materials Forward Looking Statements This presentation may contain “forward – looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include,…To view the full exhibit click here
About FORTRESS BIOTECH, INC. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
